Clinical Trials

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04034927 2026-03-18

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

61 enrolled 15 charts

Gynecologic

Fallopian Tube Neoplasms

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Phase 1 Not yet recruiting

Non Small Cell Lung Cancer NSCLC

NCT07391670 2026-03-12

IMFINZI-subQ

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01843374 2026-03-05

Tremelimumab

571 enrolled 19 charts

Phase EARLY_PHASE1 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

54 enrolled

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

301 enrolled 15 charts

Lung Cancer Metastatic

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Phase EARLY_PHASE1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

90 enrolled

Pancreatic Neoplasms

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT03965468 2026-02-09

CHESS

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03937830 2026-02-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

27 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06904170 2026-02-03

ALICE

Phase 2/3 Recruiting

196 enrolled

Carcinoma, Hepatocellular

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT03298451 2026-01-14

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Carcinoma, Hepatocellular

NCT03410615 2026-01-14

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Phase 2 Not yet recruiting

129 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT06921785 2026-01-09

ARTEMIDE-HCC01

Phase 3 Recruiting

1,220 enrolled

Carcinoma, Hepatocellular

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Phase 1 Active not recruiting

Mesothelioma

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

32 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07081633 2025-12-30

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT05380713 2025-12-29

......SMARTEST Trial......

Phase 2 Completed

30 enrolled

Mesothelioma, Malignant

NCT04960709 2025-12-19

VOLGA

712 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06880523 2025-12-18

SLIDE-HCC

140 enrolled

Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

50 enrolled

BreastDermatologicGastrointestinalThoracic

Cholangiocarcinoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Carcinoma, Hepatocellular

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06117891 2025-11-12

REFINE-IO

Recruiting

300 enrolled

Unresectable Hepatocellular Carcinoma

NCT06698250 2025-11-06

ZENOBIA

40 enrolled

Carcinoma, Hepatocellular

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06008093 2025-10-27

TRITON

Phase 3 Recruiting

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 2 FDA

Small Cell Lung Carcinoma

NCT06058663 2025-10-20

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

16 enrolled

Cholangiocarcinoma

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

52 enrolled

Phase 1 Active not recruiting

Mesothelioma

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Phase 1 Completed

13 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT04605731 2025-09-10

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

25 enrolled

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

45 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

64 enrolled